St. Bella (02508) will be offering shares from June 18th to June 23rd and is expected to be listed on June 26th.

Saint Bella (02508) will go public from June 18 to June 23, 2025, with the company planning to issue 95.42 million shares. 10% will be sold in Hong Kong and 90% internationally. The offer price per share is HK$6.58, with 500 shares per lot. Trading of the shares is expected to begin on the Stock Exchange on June 26, 2025. The company is a leading postpartum care and restoration group in China, which also provides home care services and food products to meet women's needs. The company aims to become Asia's leading comprehensive family care brand group with a growing portfolio of brands. By strengthening its presence in existing business sectors and operational markets, introducing new products to develop new business sectors such as elderly care services, and expanding its service network to promising markets beyond Mainland China, Hong Kong, Singapore, and the United States. According to a Frost & Sullivan report, the company is the largest postpartum care and restoration group in Asia and China (based on 2024 revenue from postpartum care centers), the fastest-growing scaled postpartum care and restoration group in China (based on revenue growth from 2022 to 2024), and the first postpartum care center operator in Mainland China to expand beyond Mainland China. By 2024, the company holds approximately 1.2% market share based on revenue from postpartum care centers in China. The company has entered into cornerstone investment agreements with cornerstone investors who have agreed to subscribe or cause certain entities to subscribe for a specific number of shares at a price not exceeding a total net amount of US$41.5 million (excluding underwriting commissions, SFC transaction levy, HKEx trading fee) after fulfilling certain conditions precedent (rounded down to the nearest whole trading unit of 500 shares). The company estimates that, based on the offer price per share of HK$6.58, after deducting underwriting commissions, fees, and estimated expenses payable by the company for the global offering, the company will receive a net amount of approximately HK$541 million (assuming the exercise of the over-allotment option and the additional share allotment right). Approximately 29% will be used to expand the postpartum care network, approximately 37% to introduce new services and products, approximately 6% to train professional family care experts, approximately 18% for research and development activities, and approximately 9% for operating funds and other general corporate purposes.